Advances in Clinical and Experimental Medicine

Title abbreviation: Adv Clin Exp Med
JCR Impact Factor (IF) – 1.727
Index Copernicus  – 166.39
MEiN – 70 pts

ISSN 1899–5276 (print)
ISSN 2451-2680 (online)
Periodicity – monthly

Download original text (EN)

Advances in Clinical and Experimental Medicine

2018, vol. 27, nr 8, August, p. 1149–1158

doi: 10.17219/acem/69390

Publication type: review article

Language: English

Download citation:

  • BIBTEX (JabRef, Mendeley)
  • RIS (Papers, Reference Manager, RefWorks, Zotero)

Genetic aspects of primary hyperaldosteronism

Weronika Korzyńska1,A,B,C,D, Anna Jodkowska1,A,C,D,E, Katarzyna Gosławska1,B, Katarzyna Bogunia-Kubik2,A,E,F, Grzegorz Mazur1,F

1 Department and Clinic of Internal and Occupational Diseases and Hypertension, Wroclaw Medical University, Poland

2 Laboratory of Clinical Immunogenetics and Pharmacogenetics, Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wrocław, Poland


Primary hyperaldosteronism (PHA) is the most common form of secondary hypertension of hormonal origin. It affects about 10% of all hypertensive patients. It is connected with increased morbidity and mortality from cardiovascular diseases (CVD) compared to patients with essential hypertension of a similar age. Usually, it is an effect of bilateral adrenal hyperplasia (BAH) or aldosterone-producing adenoma (APA), more rare causes of PHA are: unilateral adrenal hyperplasia, aldosterone-producing adrenocortical carcinoma, ectopic aldosterone-producing tumors and familial hyperaldosteronism. Recent genetic studies have thrown a new light on the pathogenesis of PHA, classifying it as a channelopathy. Several mutations within the ion channels encoding genes have been identified. A possible link between primary hyperaldosteronism and polymorphism of aldosterone synthase gene and ion channel genes is still being investigated. In this manuscript, we focus on genetic aspects of primary hyperaldosteronism, and present an up-to-date compilation of available data with the widened pathogenetic approach.

Key words

gene polymorphism, aldosterone, primary hyperaldosteronism, ion channels, angiotensine II

References (55)

  1. Funder JW, Carey RM, Mantero F, et al. Case detection, diagnosis, and treatment: An endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2016;101:1889–1916.
  2. Fagugli RM, Taglioni C. Changes in the perceived epidemiology of primary hyperaldosteronism. Int J Hypertens. 2011;2011:162804.
  3. Rossi GP, Bernini G, Caliumi C, et al. A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. J Am Coll Cardiol. 2006;48:2293–2300.
  4. Conn JW. Primary aldosteronism, a new clinical syndrome. J Lab Clin Med. 1955;45:3–17.
  5. Milliez P, Girerd X, Plouin PF, Blacher J, Safar ME, Mourad JJ. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol. 2005;45:1243–1248.
  6. Fallo F, Veglio F, Bertello C, et al. Prevalence and characteristics of the metabolic syndrome in primary aldosteronism. J Clin Endocrinol Metab. 2006;91:454–459.
  7. Weber KT, Brilla CG. Pathological hypertrophy and cardiac interstitium. Fibrosis and renin−angiotensin−aldosterone system. Circulation. 1991;83:1849–1865.
  8. Stowasser M, Sharman J, Leano R, et al. Evidence for abnormal left ventricular structure and function in normotensive individuals with familial hyperaldosteronism type I. J Clin Endocrinol Metab. 2005;90: 5070–5076.
  9. Sechi LA, Fabio A, Bazzocchi M, Uzzau A, Catena C. Intrarenal hemodynamics in primary aldosteronism before and after treatment. J Clin Endocrinol Metab. 2009;94:1191–1197.
  10. Freel EM, Mark PB, Weir RAP, et al. Demonstration of blood pressure-independent noninfarct myocardial fibrosis in primary aldosteronism: A cardiac magnetic resonance imaging study. Circ Cardiovasc Imaging. 2012;5:740–747.
  11. Staermose S, Marwick TH, Gordon RD, Cowley D, Dowling A, Stowasser M. Elevated serum interleukin 6 levels in normotensive individuals with familial hyperaldosteronism type 1. Hypertension. 2009;53:31–33.
  12. Bernini G, Galetta F, Franzoni F, et al. Arterial stiffness, intima-media thickness and carotid artery fibrosis in patients with primary aldosteronism. J Hypertens. 2008;26:2399–2405.
  13. Connell JMC, Davies E. The new biology of aldosterone. J Endocrinol. 2005;186:1–20.
  14. Lifton RP, Dluhy RG, Powers M, et al. A chimaeric 11 beta-hydroxylase/aldosterone synthase gene causes glucocorticoid-remediable aldosteronism and human hypertension. Nature. 1992;355:262–265.
  15. Hattangady NG, Olala LO, Bollag WB, Rainey WE. Acute and chronic regulation of aldosterone production. Mol Cell Endocrinol. 2012;350:151–162.
  16. Guagliardo NA, Yao J, Hu C, Barrett PQ: Minireview: Aldosterone biosynthesis: Electrically gated for our protection. Endocrinology. 2012;153:3579–3586.
  17. Choi M, Scholl UI, Yue P, et al. K+ channel mutations in adrenal aldosterone-producing adenomas and hereditary hypertension. Science. 2011;331:768–772.
  18. Mulatero P, Tauber P, Zennaro MC, et al. KCNJ5 mutations in European families with nonglucocorticoid remediable familial hyperaldosteronism. Hypertension. 2012;59:235–240.
  19. Azizan EAB, Murthy M, Stowasser M, et al. Somatic mutations affecting the selectivity filter of KCNJ5 are frequent in 2 large unselected collections of adrenal aldosteronomas. Hypertension. 2012;59:587–591.
  20. Åkerström T, Crona J, Delgado Verdugo A, et al. Comprehensive re-sequencing of adrenal aldosterone producing lesions reveal three somatic mutations near the KCNJ5 potassium channel selectivity filter. PLoS One. 2012;7:1–7.
  21. Williams TA, Monticone S, Schack VR, et al. Somatic ATP1A1, ATP2B3, and KCNJ5 mutations in aldosterone-producing adenomas. Hypertension. 2014;63:188–195.
  22. Scholl UI, Healy JM, Thiel A, et al. Novel somatic mutations in primary hyperaldosteronism are related to the clinical, radiological and pathological phenotype. Clin Endocrinol (Oxf). 2015;83:779–789.
  23. Zheng FF, Zhu LM, Nie AF, et al. Clinical characteristics of somatic mutations in Chinese patients with aldosterone-producing adenoma. Hypertension. 2015;65:622–628.
  24. Wang B, Li X, Zhang X, et al. Prevalence and characterization of somatic mutations in Chinese aldosterone-producing adenoma patients. Medicine (Baltimore). 2015;94:e708.
  25. Zennaro MC, Jeunemaitre X, Boulkroun S. Integrating genetics and genomics in primary aldosteronism. Hypertension. 2012;60:580–588.
  26. Åkerström T, Willenberg HS, Cupisti K, et al. Novel somatic mutations and distinct molecular signature in aldosterone-producing adenomas. Endocr Relat Cancer. 2015;22:735–744.
  27. Beuschlein F, Boulkroun S, Osswald A, et al. Somatic mutations in ATP1A1 and ATP2B3 lead to aldosterone-producing adenomas and secondary hypertension. Nat Genet. 2013;45:440–442.
  28. Azizan EA, Poulsen H, Tuluc P, et al. Somatic mutations in ATP1A1 and CACNA1D underlie a common subtype of adrenal hypertension. Nat Genet. 2013;45:1055–1060.
  29. Dutta RK, Welander J, Brauckhoff M, et al. Complementary somatic mutations of KCNJ5, ATP1A1, and ATP2B3 in sporadic aldosterone producing adrenal adenomas. Endocr Relat Cancer. 2014;21:3–6.
  30. Murakami M, Yoshimoto T, Minami I, et al. A novel somatic deletion mutation of ATP2B3 in aldosterone-producing adenoma. Endocr Pathol. 2015;26:328–333.
  31. Scholl UI, Goh G, Stölting G, et al. Somatic and germline CACNA1D calcium channel mutations in aldosterone-producing adenomas and primary aldosteronism. Nat Genet. 2013;45:1050–1054.
  32. CTNNB1 catenin beta 1. Updated June 10, 2018. Accessed June 13, 2018.
  33. Dutta RK, Soderkvist P, Grimm O. Genetics of primary hyperaldosteronism. Endocr Relat Cancer. 2016;23:R437–R454.
  34. Mulatero P, Tizzani D, Viola A, et al. Prevalence and characteristics of familial hyperaldosteronism: The PATOGEN study (Primary aldosteronism in TOrino-GENetic forms). Hypertension. 2011;58:797–803.
  35. Gordon RD, Stowasser M, Tunny TJ, Klemm SA, Finn WL, Krek AL. Clinical and pathological diversity of primary aldosteronism, including a new familial variety. Clin Exp Pharmacol Physiol. 1991;18:283–286.
  36. So A, Duffy DL, Gordon RD, et al. Familial hyperaldosteronism type II is linked to the chromosome 7p22 region but also shows predicted heterogeneity. J Hypertens. 2005;23:1477–1484.
  37. Carss KJ, Stowasser M, Gordon RD, O’Shaughnessy KM. Further study of chromosome 7p22 to identify the molecular basis of familial hyperaldosteronism type II. J Hum Hypertens. 2011;25:560–564.
  38. Geller DS, Zhang J, Wisgerhof MV, Shackleton C, Kashgarian M, Lifton RP. A novel form of human mendelian hypertension featuring nonglucocorticoid − remediable aldosteronism. J Clin Endocrinol Metab. 2008;93:3117–3123.
  39. Scholl UI, Nelson-Williams C, Yue P, et al. Hypertension with or without adrenal hyperplasia due to different inherited mutations in the potassium channel KCNJ5. Proc Natl Acad Sci USA. 2012;109:2533–2538.
  40. Charmandari E, Sertedaki A, Kino T, et al. A novel point mutation in the KCNJ5 gene causing primary hyperaldosteronism and early-onset autosomal dominant hypertension. J Clin Endocrinol Metab. 2012;97:1532–1539.
  41. Scholl UI, Stolting G, Nelson-Williams C. Recurrent gain of function mutation in calcium channel CACNA1H causes early-onset hypertension with primary aldosteronism. Elife. 2015;4:e06315. doi: 10.7554/eLife.06315
  42. CACNA1D Gene. Accessed July 27, 2016.
  43. Zilbermint M, Xekouki P, Faucz FR, et al. Primary aldosteronism and ARMC5 variants. J Clin Endocrinol Metab. 2015;100:E900–909.
  44. ARMC5 armadillo repeat containing 5. Updated June 3, 2018. Accessed June 13, 2018.
  45. Mulatero P, Schiavi F, Williams TA, et al. ARMC5 mutation analysis in patients with primary aldosteronism and bilateral adrenal lesions. J Hum Hypertens. 2016;30:374–378.
  46. Murthy M, Xu S, Massimo G, et al. Role for germline mutations and a rare coding single nucleotide polymorphism within the KCNJ5 potassium channel in a large cohort of sporadic cases of primary aldosteronism. Hypertension. 2014;63:783–789.
  47. Li N, Shi C, Li H, et al. Association of KCNJ5 gene rs3740835(C/A) and rs2604204(A/C) polymorphism with unilateral and bilateral primary aldosteronism. Chinese J Med Genet. 2014;31:233–237.
  48. White PC, Slutsker L. Haplotype analysis of CYP11B2. Endocr Res. 1995; 21:437–442.
  49. Paillard F, Chansel D, Brand E, et al. Genotype-phenotype relationships for the renin–angiotensin–aldosterone system in a normal population. Hypertension. 1999;34:423–429.
  50. Sookoian S, Gianotti TF, González CD, Pirola CJ. Association of the C-344T aldosterone synthase gene variant with essential hypertension: A meta-analysis. J Hypertens. 2007;25:5–13.
  51. Li W, Liu C. The -344C/T polymorphism in the CYP11B2 gene is associated with essential hypertension in the Chinese. JRAAS. 2014;15:150–155.
  52. Chen J, Jing J, Tan H, Song M, Yu S, Huang L. Lack of association of CYP11B2-344C/T polymorphism with essential hypertension: A meta-analysis. Int J Clin Exp Med. 2015;8:9162–9167.
  53. Inglis GC, Plouin PF, Friel EC, Davies E, Fraser R, Connell JMC. Polymorphic differences from normal in the aldosterone synthase gene (CYP11B2) in patients with primary hyperaldosteronism and adrenal tumour (Conn’s syndrome). Clin Endocrinol (Oxf). 2001;54:725–730.
  54. Jia M, Zhang H, Song X, et al. Association of CYP11B2 polymorphisms with susceptibility to primary aldosteronism: A meta-analysis. Endocr J. 2013;60:861–870.
  55. McManus F, Sands W, Diver L, et al. APEX1 regulation of aldosterone synthase gene transcription is disrupted by a common polymorphism in humans. Circ Res. 2012;111:212–219.